1. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry 
David Fiorentino, MD, PhD, Vincent Ho, MD, Mark G. Lebwohl, MD, Luiz Leite, MD, Lori Hopkins, PharmD, Claudia Galindo, MD, Kavitha Goyal, MD, Wayne Langholff, PhD, Steven Fakharzadeh, MD, PhD, Bhaskar Srivastava, MD, PhD, Richard G. Langley, MD 
Journal of the American Academy of Dermatology 
Volume 77, Issue 5, Pages e5 (November 2017)
DOI: /j.jaad
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Psoriasis. Disposition of malignancy cases and matched controls. PSOLAR, Psoriasis Longitudinal Assessment and Registry.
Journal of the American Academy of Dermatology  , e5DOI: ( /j.jaad )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Psoriasis. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of overall malignancies associated with duration of therapy with methotrexate, tumor necrosis factor-α (TNF-α) inhibitors, or ustekinumab within 12 months of exposure (primary analysis) (A), 6 months of exposure (sensitivity analysis) (B), and 24 months of exposure (sensitivity analysis) (C). *The P value comparing malignancy cases with matched controls was significant for TNF-α inhibitor treatment within the 12-month (P = .012), 6-month (P = .028), and 24-month (P = .012) exposure periods.
Journal of the American Academy of Dermatology  , e5DOI: ( /j.jaad )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

4. Supplemental Fig 1
Psoriasis. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of individual malignancies with exposure in the primary analysis for exposure to methotrexate within 12 months (A), exposure to tumor necrosis factor-α inhibitors (TNF-α) within 12 months (B), and exposure to ustekinumab within 12 months (C).*The P value comparing lung cancer cases with matched controls was significant for TNF-α inhibitor treatment (P = .028).
Journal of the American Academy of Dermatology  , e5DOI: ( /j.jaad )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions